Meeting
2019 Gastrointestinal Cancers Symposium
Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with andecaliximab combined with nivolumab versus nivolumab.
Authors
Jean-Philippe Metges
Oncology & Haematology Institute, Brest University Hospital, Brest, France
Jean-Philippe Metges , Emon Elboudwarej , David Cunningham , Daniel V.T. Catenacci , Eric Van Cutsem , Zev A. Wainberg , Yafeng Zhang , Scott Turner , Dung Thai , Pankaj Bhargava , Manish A. Shah , Carrie Brachmann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02864381
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 148)
DOI
10.1200/JCO.2019.37.4_suppl.148
Abstract #
148
Poster Bd #
L20
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Evaluation of intratumoral T cells in biopsies from advanced gastric cancer patients treated with andecaliximab and nivolumab.
First Author: Carrie Brachmann
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara
Poster
2023 ASCO Annual Meeting
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
First Author: Yelena Y. Janjigian
Poster
2019 ASCO Annual Meeting
Molecular biomarker analysis and survival in patients (pts) with advanced urothelial cancer (UC) previously treated with chemotherapy.
First Author: Bernadett Szabados